--- title: "Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma J2N-MC-JZNX | Sutter Health" description: "A Phase 2, Open-Label, Randomized Study Evaluating the Efficacy and Safety of 3 Doses of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Who Previously Received Treatment With a Covalent Bruton Tyrosine Kinase Inhibitor" url: "https://www.sutterhealth.org/research/clinical-trials/chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-j2n-mc-jznx-1095539412" --- 1. [Home](https://www.sutterhealth.org/) / 2. [Research](https://www.sutterhealth.org/research) / 3. [Clinical trials](https://www.sutterhealth.org/research/clinical-trials) / 4. Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma J2N-MC-JZNX # Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma J2N-MC-JZNX **Status:** Open to Enrollment [Email us to enroll](https://www.sutterhealth.org/research/clinical-trials/chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-j2n-mc-jznx-1095539412#enroll) #### Study details View study details on [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06588478). #### Locations - Sunnyvale - Palo Alto #### Clinical trial FAQs Information for patients and study volunteers, including [frequently asked questions](https://www.sutterhealth.org/research/faqs). The main purpose of this study is to assess the efficacy and safety of 3 dose levels of Pirtobrutinib in participants with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), who have received 1-3 lines of treatment including a covalent Bruton tyrosine kinase (BTK) inhibitor. The study is expected to last approximately 3 years. ![Roozbeh Mohajer, M.D.](https://dyn.mktgcdn.com/p/Op_knCN27cPM96InLnmEBaoxdOw7uaikg_cLB_11Q1Y/fit=crop,gravity=auto,dpr=2,width=188,height=250,quality=100) Roozbeh Mohajer, M.D. Principal investigator [View profile](https://www.sutterhealth.org/research/investigators/roozbeh-mohajer-md-2015847331) ## Email us to enroll - [Email Sunnyvale](mailto:ClinicalResearch%40sutterhealth.org?subject=More%20information%20on%20Chronic%20Lymphocytic%20Leukemia%20Small%20Lymphocytic%20Lymphoma%20J2N-MC-JZNX%20in%20Sunnyvale&body=Please%20be%20aware%20that%20if%20you%20reply%20with%20unencrypted%20email%2C%20this%20increases%20the%20risk%20that%20information%20could%20be%20read%20by%20an%20unauthorized%20third%20party.%20Please%20do%20not%20include%20any%20Protected%20Health%20Information%20in%20your%20email%20response.) - [Email Palo Alto](mailto:ClinicalResearch%40sutterhealth.org?subject=More%20information%20on%20Chronic%20Lymphocytic%20Leukemia%20Small%20Lymphocytic%20Lymphoma%20J2N-MC-JZNX%20in%20Palo%20Alto&body=Please%20be%20aware%20that%20if%20you%20reply%20with%20unencrypted%20email%2C%20this%20increases%20the%20risk%20that%20information%20could%20be%20read%20by%20an%20unauthorized%20third%20party.%20Please%20do%20not%20include%20any%20Protected%20Health%20Information%20in%20your%20email%20response.) ## Related clinical trials [View all clinical trials](https://www.sutterhealth.org/research-search-results?verticalKey=clinical_trial) - Clinical trial ### [Interventional Myeloma EQUATE EAA181](https://www.sutterhealth.org/research/clinical-trials/interventional-myeloma-equate-eaa181-1049141964) Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation **Status:** Open to Enrollment - Clinical trial ### [Multiple Myeloma Expanded Access to Ciltacabtagene Autoleucel (Cilta-Cel) 68284528MMY4006](https://www.sutterhealth.org/research/clinical-trials/multiple-myeloma-expanded-access-to-ciltacabtagene-autoleucel-cilta-cel-68284528mmy4006-2048816446) Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-cel) Out-of-Specification (OOS) in Patients With Multiple Myeloma **Status:** Open to Enrollment - Clinical trial ### [Multiple Myeloma Expanded Access to Idecabtagene Vicleucel BB2121-EAP-001](https://www.sutterhealth.org/research/clinical-trials/multiple-myeloma-expanded-access-to-idecabtagene-vicleucel-bb2121-eap-001-2062975937) Expanded Access Protocol (EAP) for Patients Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release **Status:** Coming Soon - Clinical trial ### [Adjuvant Large B-Cell Lymphoma Alpha3](https://www.sutterhealth.org/research/clinical-trials/adjuvant-large-b-cell-lymphoma-alpha3-1095534994) A Randomized, Open-label Study Evaluating the Efficacy and Safety of Cemacabtagene Ansegedleucel in Participants With Minimal Residual Disease After Response to First Line Therapy for Large B-cell Lymphoma **Status:** Open to Enrollment - Clinical trial ### [Cancer Young Female Adults Ovarian Damage Prevention ALTE2131](https://www.sutterhealth.org/research/clinical-trials/cancer-young-female-adults-ovarian-damage-prevention-alte2131-2027477841) Triptorelin and Protection of Ovarian Reserve in Adolescents and Young Adults With Cancer **Status:** Open to Enrollment [View all clinical trials](https://www.sutterhealth.org/research-search-results?verticalKey=clinical_trial) ```json {"@context":"https://schema.org","@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org","logo":"https://www.sutterhealth.org/static/images/sutter-health-logo.svg","address":{"@type":"PostalAddress","streetAddress":"2200 River Plaza Drive","addressLocality":"Sacramento","addressRegion":"CA","postalCode":"95833","addressCountry":"US"},"areaServed":{"@type":"AdministrativeArea","name":"California"},"sameAs":["https://www.facebook.com/SutterHealth","https://www.instagram.com/sutterhealth/","https://x.com/SutterHealth","https://www.youtube.com/sutterhealth","https://www.linkedin.com/company/sutter-health","https://en.wikipedia.org/wiki/Sutter_Health"]} ``` ```json {"@context":"https://schema.org","@type":"BreadcrumbList","@id":"https://www.sutterhealth.org/research/clinical-trials/chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-j2n-mc-jznx-1095539412#breadcrumblist","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://www.sutterhealth.org/"},{"@type":"ListItem","position":2,"name":"Research","item":"https://www.sutterhealth.org/research"},{"@type":"ListItem","position":3,"name":"Clinical trials","item":"https://www.sutterhealth.org/research/clinical-trials"},{"@type":"ListItem","position":4,"name":"Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma J2N-MC-JZNX"}]} ``` ```json {"@context":"https://schema.org","@type":"MedicalWebPage","@id":"https://www.sutterhealth.org/research/clinical-trials/chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-j2n-mc-jznx-1095539412#medicalwebpage","name":"Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma J2N-MC-JZNX","description":"A Phase 2, Open-Label, Randomized Study Evaluating the Efficacy and Safety of 3 Doses of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Who Previously Received Treatment With a Covalent Bruton Tyrosine Kinase Inhibitor","url":"https://www.sutterhealth.org/research/clinical-trials/chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-j2n-mc-jznx-1095539412","inLanguage":"en-US","dateModified":"2026-05-21","publisher":{"@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org"},"medicalAudience":{"@type":"MedicalAudience","audienceType":"Patient"},"mainEntity":{"@id":"https://www.sutterhealth.org/research/clinical-trials/chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-j2n-mc-jznx-1095539412#medicaltrial"},"breadcrumb":{"@id":"https://www.sutterhealth.org/research/clinical-trials/chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-j2n-mc-jznx-1095539412#breadcrumblist"},"mentions":[{"@type":"Person","name":"Roozbeh Mohajer, M.D.","url":"https://www.sutterhealth.org/research/investigators/roozbeh-mohajer-md-2015847331","jobTitle":"Principal Investigator","affiliation":{"@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org"}}]} ``` ```json {"@context":"https://schema.org","@type":"MedicalTrial","@id":"https://www.sutterhealth.org/research/clinical-trials/chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-j2n-mc-jznx-1095539412#medicaltrial","name":"Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma J2N-MC-JZNX","alternateName":"A Phase 2, Open-Label, Randomized Study Evaluating the Efficacy and Safety of 3 Doses of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Who Previously Received Treatment With a Covalent Bruton Tyrosine Kinase Inhibitor","url":"https://www.sutterhealth.org/research/clinical-trials/chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-j2n-mc-jznx-1095539412","description":"The main purpose of this study is to assess the efficacy and safety of 3 dose levels of Pirtobrutinib in participants with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), who have received 1-3 lines of treatment including a covalent Bruton tyrosine kinase (BTK) inhibitor. The study is expected to last approximately 3 years.","identifier":"NCT06588478","code":{"@type":"MedicalCode","codeValue":"NCT06588478","codingSystem":"ClinicalTrials.gov"},"sameAs":"https://clinicaltrials.gov/study/NCT06588478","status":"https://schema.org/Recruiting","healthCondition":[{"@type":"MedicalCondition","name":"Leukemia"},{"@type":"MedicalCondition","name":"Hematologic Cancer"}],"studyLocation":[{"@type":"AdministrativeArea","name":"Sunnyvale"},{"@type":"AdministrativeArea","name":"Palo Alto"}]} ```